Page last updated: 2024-12-07

e 64

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

E 64: cysteine protease inhibitor of microbial origin, which inhibits cathepsin B (EC 3.4.22.1) and cathepsin L (EC 3.4.22.-) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123985
CHEMBL ID374508
CHEBI ID30270
SCHEMBL ID4740187
MeSH IDM0083791

Synonyms (43)

Synonym
CHEBI:30270 ,
e 64 (proteinase inhibitor)
brn 1405664
oxiranecarboxylic acid, 3-(((1-(((4-((aminoiminomethyl)amino)butyl)amino)carbonyl)-3-methylbutyl)amino)carbonyl)-, (2s-(2-alpha,3-beta(r*)))-
e 64
oxiranecarboxylic acid, 3-(((1-(((4-((aminoiminomethyl)amino)butyl)amino)carbonyl)-3-methylbutyl)amino)carbonyl)-, (2s-(2alpha,3beta(r*)))-
thiol protease inhibitor
C01341
66701-25-5
e-64 ,
NCGC00163544-01
(2s,3s)-3-((s)-1-(4-guanidinobutylamino)-4-methyl-1-oxopentan-2-ylcarbamoyl)oxirane-2-carboxylic acid
chembl374508 ,
bdbm50157741
(2s,3s)-3-[[(2s)-1-[4-(diaminomethylideneamino)butylamino]-4-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylic acid
3-[[1-[4-(diaminomethylideneamino)butylamino]-4-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylic acid
(2s,3s)-3-(((s)-1-((4-guanidinobutyl)amino)-4-methyl-1-oxopentan-2-yl)carbamoyl)oxirane-2-carboxylic acid
AKOS016007415
r76f7856mv ,
5-18-07-00006 (beilstein handbook reference)
unii-r76f7856mv
proteinase inhibitor e-64
2-oxiranecarboxylic acid, 3-((((1s)-1-(((4-((aminoiminomethyl)amino)butyl)amino)carbonyl)-3-methylbutyl)amino)carbonyl)-, (2s,3s)-
CCG-207844
CCG-208198
(2s,3s)-3-[[(1s)-1-(4-guanidinobutylcarbamoyl)-3-methyl-butyl]carbamoyl]oxirane-2-carboxylic acid
CS-4140
SCHEMBL4740187
(2s,3s)-3-[[[(1s)-1-[[[4-(aminoiminomethyl)amino]butyl]amino]carbonyl]-3-methylbutyl]amino]carbonyl]-2-oxiranecarboxylic acid
2-oxiranecarboxylic acid, 3-[[[(1s)-1-[[[4-[(aminoiminomethyl)amino]butyl]amino]carbonyl]-3-methylbutyl]amino]carbonyl]-, (2s,3s)-
FD21944
HY-15282
mfcd00080261
trans-epoxysuccinyl-l-leucylamido-(4-guanidino)butane
E-0010
(l-3-trans-carboxyoxirane-2-carbonyl)-l-leucylagmatine hemihydrate
(2s,3s)-3-(n-{(s)-1-[n-(4-guanidinobutyl)carbamoyl]3-methylbutyl}carbamoyl)oxirane-2-carboxylic acid
Q5321373
EX-A2284
80408-29-3
3-[[[(1s)-1-[[[4-[(aminoiminomethyl)amino]butyl]amino]carbonyl]-3-methylbutyl]amino]carbonyl]-(2s,3s)-oxiranecarboxylic acid
NCGC00163544-09
AC-36011

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" A direct toxic effect of CsA on renal tubule epithelia was demonstrated using nigrosine uptake and LDH release as indicators of cell death."( Mechanisms of cyclosporine A toxicity in defined cultures of renal tubule epithelia: a role for cysteine proteases.
Hartz, PA; Wilson, PD, 1991
)
0.28
" Among various processes that have been thought to mediate the toxic effects of glutamate are activation of the Ca(2+)-dependent proteases calpain I and II and the activation of nitric oxide synthase."( Delayed antagonism of calpain reduces excitotoxicity in cultured neurons.
Brorson, JR; Marcuccilli, CJ; Miller, RJ, 1995
)
0.29
" This inhibitor also limited the toxicity, even when applied at times up to 1 hour after the onset of the toxic exposure."( Delayed antagonism of calpain reduces excitotoxicity in cultured neurons.
Brorson, JR; Marcuccilli, CJ; Miller, RJ, 1995
)
0.29

Dosage Studied

ExcerptRelevanceReference
" The time course and dose-response of lysosomal cathepsin B activity to E-64 were closely related to the radioactivity in the protein-bound fraction of the lysosomes."( Inhibitions of cathepsin B and cathepsin L by E-64 in vivo. II. Incorporation of [3H]E-64 into rat liver lysosomes in vivo.
Hashida, S; Katunuma, N; Kominami, E, 1982
)
0.26
" Incorporation of polar or charged functional groups in the inhibitor structure afforded effective cathepsin B inhibition, following dosing to rats."( In vivo inhibition of cathepsin B by peptidyl (acyloxy)methyl ketones.
Coles, PJ; Copp, LJ; Ernest, MJ; Krantz, A; Smith, RA; Wagner, BM, 1994
)
0.29
" The released T-2513 levels in the liver and tumor of the tumor-bearing rats dosed with each conjugate increased with the length of Gly linker, suggesting a good in vitro to in vivo relationship."( Determinants for the drug release from T-0128, camptothecin analogue-carboxymethyl dextran conjugate.
Harada, M; Okuno, S; Sakakibara, H; Suzuki, T; Yano, T, 2000
)
0.31
" The aim of this study was to establish the dose-response relationship of the inhibition of proteolysis as assessed by FIZ with E-64 at different dosages in a murine model of fasciolosis."( Dose-response inhibition of proteolytic activity by a cysteine protease inhibitor in a murine model of fasciolosis.
Alberti-Navarro, A; Alcalá-Canto, Y; Gracia-Mora, J; Ibarra-Velarde, F; Sumano-Lopez, H, 2006
)
0.33
" This can confound predictions based solely on inhibitor kinetics, and must be better understood to effectively deploy therapies and dosing strategies that target cathepsins to prevent cancer progression."( Differential cathepsin responses to inhibitor-induced feedback: E-64 and cystatin C elevate active cathepsin S and suppress active cathepsin L in breast cancer cells.
Johnson, J; Odero-Marah, V; Payne, CK; Peyton, SR; Platt, MO; Stewart, FAA; Walton, C; Watson, V; Wilder, CL, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
protease inhibitorA compound which inhibits or antagonizes the biosynthesis or actions of proteases (endopeptidases).
antimalarialA drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human.
antiparasitic agentA substance used to treat or prevent parasitic infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
epoxy monocarboxylic acidMonocarboxylic acids containing at least one epoxy group.
dicarboxylic acid monoamide
guanidinesAny organonitrogen compound containing a carbamimidamido (guanidino) group. Guanidines have the general structure (R(1)R(2)N)(R(3)R(4)N)C=N-R(5) and are related structurally to amidines and ureas.
L-leucine derivativeA proteinogenic amino acid derivative resulting from reaction of L-leucine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-leucine by a heteroatom.
zwitterionA neutral compound having formal unit electrical charges of opposite sign on non-adjacent atoms. Sometimes referred to as inner salts, dipolar ions (a misnomer).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA polymerase kappa isoform 1Homo sapiens (human)Potency29.93490.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Calpain-9Homo sapiens (human)IC50 (µMol)11.58001.61003.97609.8800AID1620950
PapainCarica papaya (papaya)IC50 (µMol)0.01870.00201.504510.0000AID351452; AID635272; AID775984
PapainCarica papaya (papaya)Ki5.08002.40003.74005.0800AID762419
Calpain-1 catalytic subunitHomo sapiens (human)IC50 (µMol)0.10000.00021.059210.0000AID762422
Procathepsin LHomo sapiens (human)IC50 (µMol)0.02790.00021.66619.5100AID1170652; AID1854036; AID360105; AID454720; AID51350
Procathepsin LHomo sapiens (human)Ki0.03000.00001.10139.3000AID1458683
Cathepsin BHomo sapiens (human)IC50 (µMol)0.01760.00021.845310.0000AID1170651; AID1854035; AID360103; AID50272
Cathepsin BHomo sapiens (human)Ki16.00000.00001.21808.6000AID454719
Neutrophil elastaseHomo sapiens (human)IC50 (µMol)300.00000.00632.073422.3780AID279734
Pro-cathepsin HHomo sapiens (human)IC50 (µMol)0.19000.12592.740410.0000AID360106
Lysosomal protective proteinHomo sapiens (human)IC50 (µMol)300.00000.60006.600010.0000AID279732
Fatty acid synthase Rattus norvegicus (Norway rat)IC50 (µMol)300.00000.05000.05000.0500AID279735
Cathepsin SHomo sapiens (human)IC50 (µMol)0.00700.00021.319110.0000AID360104
CruzipainTrypanosoma cruziIC50 (µMol)0.21000.00022.04508.0000AID1312174; AID1754247
Calpain-1 catalytic subunitSus scrofa (pig)Ki3.96000.01000.86403.9600AID762420
Dipeptidyl peptidase 1Homo sapiens (human)IC50 (µMol)0.77000.03473.151510.0000AID360102
Liver carboxylesteraseSus scrofa (pig)IC50 (µMol)300.00000.00240.93591.8000AID279735
Cysteine protease Trypanosoma brucei rhodesienseIC50 (µMol)0.00310.00313.87667.7500AID1754249
Cysteine protease Trypanosoma brucei rhodesienseKi0.03500.03502.55175.3100AID1458695
Cysteine proteinase falcipain 2a Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)0.08280.00580.44035.0000AID1458688; AID240752; AID261349; AID282100; AID461168; AID587701
Cysteine proteinase falcipain 2a Plasmodium falciparum (malaria parasite P. falciparum)Ki13.62670.29000.29000.2900AID315749; AID490970; AID492329
Cysteine protease falcipain-3Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)0.48150.08700.22220.4815AID587702
Cysteine protease falcipain-3Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)0.05500.03500.05500.0750AID261350; AID282101
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (87)

Processvia Protein(s)Taxonomy
digestionCalpain-9Homo sapiens (human)
proteolysisCalpain-9Homo sapiens (human)
proteolysisCalpain-1 catalytic subunitHomo sapiens (human)
positive regulation of cell population proliferationCalpain-1 catalytic subunitHomo sapiens (human)
regulation of macroautophagyCalpain-1 catalytic subunitHomo sapiens (human)
receptor catabolic processCalpain-1 catalytic subunitHomo sapiens (human)
regulation of catalytic activityCalpain-1 catalytic subunitHomo sapiens (human)
mammary gland involutionCalpain-1 catalytic subunitHomo sapiens (human)
self proteolysisCalpain-1 catalytic subunitHomo sapiens (human)
regulation of NMDA receptor activityCalpain-1 catalytic subunitHomo sapiens (human)
adaptive immune responseProcathepsin LHomo sapiens (human)
proteolysisProcathepsin LHomo sapiens (human)
protein autoprocessingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host plasma membraneProcathepsin LHomo sapiens (human)
receptor-mediated endocytosis of virus by host cellProcathepsin LHomo sapiens (human)
antigen processing and presentationProcathepsin LHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIProcathepsin LHomo sapiens (human)
collagen catabolic processProcathepsin LHomo sapiens (human)
zymogen activationProcathepsin LHomo sapiens (human)
enkephalin processingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host endosome membraneProcathepsin LHomo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitmentProcathepsin LHomo sapiens (human)
symbiont entry into host cellProcathepsin LHomo sapiens (human)
antigen processing and presentation of peptide antigenProcathepsin LHomo sapiens (human)
proteolysis involved in protein catabolic processProcathepsin LHomo sapiens (human)
elastin catabolic processProcathepsin LHomo sapiens (human)
macrophage apoptotic processProcathepsin LHomo sapiens (human)
cellular response to thyroid hormone stimulusProcathepsin LHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProcathepsin LHomo sapiens (human)
positive regulation of peptidase activityProcathepsin LHomo sapiens (human)
immune responseProcathepsin LHomo sapiens (human)
proteolysisCathepsin BHomo sapiens (human)
thyroid hormone generationCathepsin BHomo sapiens (human)
collagen catabolic processCathepsin BHomo sapiens (human)
epithelial cell differentiationCathepsin BHomo sapiens (human)
regulation of apoptotic processCathepsin BHomo sapiens (human)
decidualizationCathepsin BHomo sapiens (human)
symbiont entry into host cellCathepsin BHomo sapiens (human)
proteolysis involved in protein catabolic processCathepsin BHomo sapiens (human)
cellular response to thyroid hormone stimulusCathepsin BHomo sapiens (human)
proteolysisNeutrophil elastaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINeutrophil elastaseHomo sapiens (human)
response to yeastNeutrophil elastaseHomo sapiens (human)
leukocyte migration involved in inflammatory responseNeutrophil elastaseHomo sapiens (human)
biosynthetic process of antibacterial peptides active against Gram-negative bacteriaNeutrophil elastaseHomo sapiens (human)
proteolysisNeutrophil elastaseHomo sapiens (human)
intracellular calcium ion homeostasisNeutrophil elastaseHomo sapiens (human)
response to UVNeutrophil elastaseHomo sapiens (human)
extracellular matrix disassemblyNeutrophil elastaseHomo sapiens (human)
protein catabolic processNeutrophil elastaseHomo sapiens (human)
response to lipopolysaccharideNeutrophil elastaseHomo sapiens (human)
negative regulation of chemokine productionNeutrophil elastaseHomo sapiens (human)
negative regulation of interleukin-8 productionNeutrophil elastaseHomo sapiens (human)
positive regulation of interleukin-8 productionNeutrophil elastaseHomo sapiens (human)
defense response to bacteriumNeutrophil elastaseHomo sapiens (human)
positive regulation of MAP kinase activityNeutrophil elastaseHomo sapiens (human)
positive regulation of smooth muscle cell proliferationNeutrophil elastaseHomo sapiens (human)
negative regulation of inflammatory responseNeutrophil elastaseHomo sapiens (human)
positive regulation of immune responseNeutrophil elastaseHomo sapiens (human)
negative regulation of chemotaxisNeutrophil elastaseHomo sapiens (human)
pyroptosisNeutrophil elastaseHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumNeutrophil elastaseHomo sapiens (human)
neutrophil-mediated killing of fungusNeutrophil elastaseHomo sapiens (human)
positive regulation of leukocyte tethering or rollingNeutrophil elastaseHomo sapiens (human)
phagocytosisNeutrophil elastaseHomo sapiens (human)
acute inflammatory response to antigenic stimulusNeutrophil elastaseHomo sapiens (human)
metanephros developmentPro-cathepsin HHomo sapiens (human)
T cell mediated cytotoxicityPro-cathepsin HHomo sapiens (human)
adaptive immune responsePro-cathepsin HHomo sapiens (human)
immune response-regulating signaling pathwayPro-cathepsin HHomo sapiens (human)
proteolysisPro-cathepsin HHomo sapiens (human)
apoptotic processPro-cathepsin HHomo sapiens (human)
positive regulation of cell population proliferationPro-cathepsin HHomo sapiens (human)
positive regulation of gene expressionPro-cathepsin HHomo sapiens (human)
positive regulation of epithelial cell migrationPro-cathepsin HHomo sapiens (human)
neuropeptide catabolic processPro-cathepsin HHomo sapiens (human)
bradykinin catabolic processPro-cathepsin HHomo sapiens (human)
positive regulation of peptidase activityPro-cathepsin HHomo sapiens (human)
antigen processing and presentationPro-cathepsin HHomo sapiens (human)
positive regulation of cell migrationPro-cathepsin HHomo sapiens (human)
zymogen activationPro-cathepsin HHomo sapiens (human)
protein destabilizationPro-cathepsin HHomo sapiens (human)
response to retinoic acidPro-cathepsin HHomo sapiens (human)
membrane protein proteolysisPro-cathepsin HHomo sapiens (human)
negative regulation of apoptotic processPro-cathepsin HHomo sapiens (human)
surfactant homeostasisPro-cathepsin HHomo sapiens (human)
positive regulation of angiogenesisPro-cathepsin HHomo sapiens (human)
dichotomous subdivision of terminal units involved in lung branchingPro-cathepsin HHomo sapiens (human)
ERK1 and ERK2 cascadePro-cathepsin HHomo sapiens (human)
cellular response to thyroid hormone stimulusPro-cathepsin HHomo sapiens (human)
positive regulation of apoptotic signaling pathwayPro-cathepsin HHomo sapiens (human)
proteolysis involved in protein catabolic processPro-cathepsin HHomo sapiens (human)
immune responsePro-cathepsin HHomo sapiens (human)
proteolysisLysosomal protective proteinHomo sapiens (human)
intracellular protein transportLysosomal protective proteinHomo sapiens (human)
regulation of protein stabilityLysosomal protective proteinHomo sapiens (human)
regulation of chaperone-mediated autophagyLysosomal protective proteinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyLysosomal protective proteinHomo sapiens (human)
toll-like receptor signaling pathwayCathepsin SHomo sapiens (human)
adaptive immune responseCathepsin SHomo sapiens (human)
proteolysisCathepsin SHomo sapiens (human)
apoptotic processCathepsin SHomo sapiens (human)
response to acidic pHCathepsin SHomo sapiens (human)
protein processingCathepsin SHomo sapiens (human)
antigen processing and presentationCathepsin SHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IICathepsin SHomo sapiens (human)
extracellular matrix disassemblyCathepsin SHomo sapiens (human)
collagen catabolic processCathepsin SHomo sapiens (human)
basement membrane disassemblyCathepsin SHomo sapiens (human)
antigen processing and presentation of peptide antigenCathepsin SHomo sapiens (human)
proteolysis involved in protein catabolic processCathepsin SHomo sapiens (human)
cellular response to thyroid hormone stimulusCathepsin SHomo sapiens (human)
positive regulation of cation channel activityCathepsin SHomo sapiens (human)
positive regulation of peptidase activityCathepsin SHomo sapiens (human)
immune responseCathepsin SHomo sapiens (human)
positive regulation of apoptotic signaling pathwayCathepsin SHomo sapiens (human)
T cell mediated cytotoxicityDipeptidyl peptidase 1Homo sapiens (human)
proteolysisDipeptidyl peptidase 1Homo sapiens (human)
apoptotic processDipeptidyl peptidase 1Homo sapiens (human)
immune responseDipeptidyl peptidase 1Homo sapiens (human)
response to organic substanceDipeptidyl peptidase 1Homo sapiens (human)
negative regulation of myelinationDipeptidyl peptidase 1Homo sapiens (human)
positive regulation of proteolysis involved in protein catabolic processDipeptidyl peptidase 1Homo sapiens (human)
positive regulation of microglial cell activationDipeptidyl peptidase 1Homo sapiens (human)
positive regulation of apoptotic signaling pathwayDipeptidyl peptidase 1Homo sapiens (human)
proteolysis involved in protein catabolic processDipeptidyl peptidase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (31)

Processvia Protein(s)Taxonomy
calcium ion bindingCalpain-9Homo sapiens (human)
calcium-dependent cysteine-type endopeptidase activityCalpain-9Homo sapiens (human)
calcium-dependent cysteine-type endopeptidase activityCalpain-1 catalytic subunitHomo sapiens (human)
calcium ion bindingCalpain-1 catalytic subunitHomo sapiens (human)
protein bindingCalpain-1 catalytic subunitHomo sapiens (human)
peptidase activityCalpain-1 catalytic subunitHomo sapiens (human)
fibronectin bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityProcathepsin LHomo sapiens (human)
protein bindingProcathepsin LHomo sapiens (human)
collagen bindingProcathepsin LHomo sapiens (human)
cysteine-type peptidase activityProcathepsin LHomo sapiens (human)
histone bindingProcathepsin LHomo sapiens (human)
proteoglycan bindingProcathepsin LHomo sapiens (human)
serpin family protein bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityCathepsin BHomo sapiens (human)
protein bindingCathepsin BHomo sapiens (human)
collagen bindingCathepsin BHomo sapiens (human)
peptidase activityCathepsin BHomo sapiens (human)
cysteine-type peptidase activityCathepsin BHomo sapiens (human)
proteoglycan bindingCathepsin BHomo sapiens (human)
protease bindingNeutrophil elastaseHomo sapiens (human)
transcription corepressor activityNeutrophil elastaseHomo sapiens (human)
endopeptidase activityNeutrophil elastaseHomo sapiens (human)
serine-type endopeptidase activityNeutrophil elastaseHomo sapiens (human)
protein bindingNeutrophil elastaseHomo sapiens (human)
heparin bindingNeutrophil elastaseHomo sapiens (human)
peptidase activityNeutrophil elastaseHomo sapiens (human)
cytokine bindingNeutrophil elastaseHomo sapiens (human)
endopeptidase activityPro-cathepsin HHomo sapiens (human)
aminopeptidase activityPro-cathepsin HHomo sapiens (human)
cysteine-type endopeptidase activityPro-cathepsin HHomo sapiens (human)
serine-type endopeptidase activityPro-cathepsin HHomo sapiens (human)
protein bindingPro-cathepsin HHomo sapiens (human)
peptidase activityPro-cathepsin HHomo sapiens (human)
cysteine-type peptidase activityPro-cathepsin HHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processPro-cathepsin HHomo sapiens (human)
HLA-A specific activating MHC class I receptor activityPro-cathepsin HHomo sapiens (human)
thyroid hormone bindingPro-cathepsin HHomo sapiens (human)
carboxypeptidase activityLysosomal protective proteinHomo sapiens (human)
serine-type carboxypeptidase activityLysosomal protective proteinHomo sapiens (human)
enzyme activator activityLysosomal protective proteinHomo sapiens (human)
fibronectin bindingCathepsin SHomo sapiens (human)
cysteine-type endopeptidase activityCathepsin SHomo sapiens (human)
serine-type endopeptidase activityCathepsin SHomo sapiens (human)
collagen bindingCathepsin SHomo sapiens (human)
laminin bindingCathepsin SHomo sapiens (human)
proteoglycan bindingCathepsin SHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processCathepsin SHomo sapiens (human)
serine-type endopeptidase activityDipeptidyl peptidase 1Homo sapiens (human)
protein bindingDipeptidyl peptidase 1Homo sapiens (human)
cysteine-type peptidase activityDipeptidyl peptidase 1Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 1Homo sapiens (human)
peptidase activator activity involved in apoptotic processDipeptidyl peptidase 1Homo sapiens (human)
phosphatase bindingDipeptidyl peptidase 1Homo sapiens (human)
chloride ion bindingDipeptidyl peptidase 1Homo sapiens (human)
identical protein bindingDipeptidyl peptidase 1Homo sapiens (human)
protein-folding chaperone bindingDipeptidyl peptidase 1Homo sapiens (human)
cysteine-type endopeptidase activityDipeptidyl peptidase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (47)

Processvia Protein(s)Taxonomy
cellular_componentCalpain-9Homo sapiens (human)
cytoplasmCalpain-9Homo sapiens (human)
cornified envelopeCalpain-1 catalytic subunitHomo sapiens (human)
extracellular regionCalpain-1 catalytic subunitHomo sapiens (human)
mitochondrionCalpain-1 catalytic subunitHomo sapiens (human)
lysosomeCalpain-1 catalytic subunitHomo sapiens (human)
cytosolCalpain-1 catalytic subunitHomo sapiens (human)
plasma membraneCalpain-1 catalytic subunitHomo sapiens (human)
focal adhesionCalpain-1 catalytic subunitHomo sapiens (human)
membraneCalpain-1 catalytic subunitHomo sapiens (human)
extracellular exosomeCalpain-1 catalytic subunitHomo sapiens (human)
calpain complexCalpain-1 catalytic subunitHomo sapiens (human)
ficolin-1-rich granule lumenCalpain-1 catalytic subunitHomo sapiens (human)
cytoplasmCalpain-1 catalytic subunitHomo sapiens (human)
extracellular regionProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
nucleusProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
multivesicular bodyProcathepsin LHomo sapiens (human)
Golgi apparatusProcathepsin LHomo sapiens (human)
plasma membraneProcathepsin LHomo sapiens (human)
apical plasma membraneProcathepsin LHomo sapiens (human)
endolysosome lumenProcathepsin LHomo sapiens (human)
chromaffin granuleProcathepsin LHomo sapiens (human)
lysosomal lumenProcathepsin LHomo sapiens (human)
intracellular membrane-bounded organelleProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixProcathepsin LHomo sapiens (human)
extracellular exosomeProcathepsin LHomo sapiens (human)
endocytic vesicle lumenProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixCathepsin BHomo sapiens (human)
extracellular regionCathepsin BHomo sapiens (human)
extracellular spaceCathepsin BHomo sapiens (human)
lysosomeCathepsin BHomo sapiens (human)
external side of plasma membraneCathepsin BHomo sapiens (human)
apical plasma membraneCathepsin BHomo sapiens (human)
endolysosome lumenCathepsin BHomo sapiens (human)
melanosomeCathepsin BHomo sapiens (human)
perinuclear region of cytoplasmCathepsin BHomo sapiens (human)
collagen-containing extracellular matrixCathepsin BHomo sapiens (human)
extracellular exosomeCathepsin BHomo sapiens (human)
peptidase inhibitor complexCathepsin BHomo sapiens (human)
ficolin-1-rich granule lumenCathepsin BHomo sapiens (human)
extracellular spaceCathepsin BHomo sapiens (human)
lysosomeCathepsin BHomo sapiens (human)
extracellular regionNeutrophil elastaseHomo sapiens (human)
extracellular spaceNeutrophil elastaseHomo sapiens (human)
cytoplasmNeutrophil elastaseHomo sapiens (human)
cytosolNeutrophil elastaseHomo sapiens (human)
cell surfaceNeutrophil elastaseHomo sapiens (human)
secretory granuleNeutrophil elastaseHomo sapiens (human)
azurophil granule lumenNeutrophil elastaseHomo sapiens (human)
specific granule lumenNeutrophil elastaseHomo sapiens (human)
phagocytic vesicleNeutrophil elastaseHomo sapiens (human)
collagen-containing extracellular matrixNeutrophil elastaseHomo sapiens (human)
extracellular exosomeNeutrophil elastaseHomo sapiens (human)
transcription repressor complexNeutrophil elastaseHomo sapiens (human)
extracellular spaceNeutrophil elastaseHomo sapiens (human)
extracellular regionPro-cathepsin HHomo sapiens (human)
extracellular spacePro-cathepsin HHomo sapiens (human)
lysosomePro-cathepsin HHomo sapiens (human)
cytosolPro-cathepsin HHomo sapiens (human)
secretory granule lumenPro-cathepsin HHomo sapiens (human)
cytoplasmic ribonucleoprotein granulePro-cathepsin HHomo sapiens (human)
intracellular membrane-bounded organellePro-cathepsin HHomo sapiens (human)
collagen-containing extracellular matrixPro-cathepsin HHomo sapiens (human)
extracellular exosomePro-cathepsin HHomo sapiens (human)
alveolar lamellar bodyPro-cathepsin HHomo sapiens (human)
multivesicular body lumenPro-cathepsin HHomo sapiens (human)
tertiary granule lumenPro-cathepsin HHomo sapiens (human)
ficolin-1-rich granule lumenPro-cathepsin HHomo sapiens (human)
extracellular spacePro-cathepsin HHomo sapiens (human)
lysosomePro-cathepsin HHomo sapiens (human)
lumenal side of lysosomal membraneLysosomal protective proteinHomo sapiens (human)
extracellular regionLysosomal protective proteinHomo sapiens (human)
lysosomeLysosomal protective proteinHomo sapiens (human)
endoplasmic reticulumLysosomal protective proteinHomo sapiens (human)
membraneLysosomal protective proteinHomo sapiens (human)
azurophil granule lumenLysosomal protective proteinHomo sapiens (human)
lysosomal lumenLysosomal protective proteinHomo sapiens (human)
intracellular membrane-bounded organelleLysosomal protective proteinHomo sapiens (human)
extracellular exosomeLysosomal protective proteinHomo sapiens (human)
cytosolFatty acid synthase Rattus norvegicus (Norway rat)
extracellular regionCathepsin SHomo sapiens (human)
extracellular spaceCathepsin SHomo sapiens (human)
lysosomeCathepsin SHomo sapiens (human)
late endosomeCathepsin SHomo sapiens (human)
endolysosome lumenCathepsin SHomo sapiens (human)
lysosomal lumenCathepsin SHomo sapiens (human)
intracellular membrane-bounded organelleCathepsin SHomo sapiens (human)
phagocytic vesicleCathepsin SHomo sapiens (human)
collagen-containing extracellular matrixCathepsin SHomo sapiens (human)
tertiary granule lumenCathepsin SHomo sapiens (human)
ficolin-1-rich granule lumenCathepsin SHomo sapiens (human)
extracellular spaceCathepsin SHomo sapiens (human)
lysosomeCathepsin SHomo sapiens (human)
extracellular regionDipeptidyl peptidase 1Homo sapiens (human)
extracellular spaceDipeptidyl peptidase 1Homo sapiens (human)
nucleoplasmDipeptidyl peptidase 1Homo sapiens (human)
lysosomeDipeptidyl peptidase 1Homo sapiens (human)
endoplasmic reticulum lumenDipeptidyl peptidase 1Homo sapiens (human)
centrosomeDipeptidyl peptidase 1Homo sapiens (human)
membraneDipeptidyl peptidase 1Homo sapiens (human)
COPII-coated ER to Golgi transport vesicleDipeptidyl peptidase 1Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membraneDipeptidyl peptidase 1Homo sapiens (human)
azurophil granule lumenDipeptidyl peptidase 1Homo sapiens (human)
intracellular membrane-bounded organelleDipeptidyl peptidase 1Homo sapiens (human)
collagen-containing extracellular matrixDipeptidyl peptidase 1Homo sapiens (human)
extracellular exosomeDipeptidyl peptidase 1Homo sapiens (human)
lysosomeDipeptidyl peptidase 1Homo sapiens (human)
extracellular spaceDipeptidyl peptidase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (203)

Assay IDTitleYearJournalArticle
AID282100Inhibition of Plasmodium falciparum recombinant falcipain-22004Journal of medicinal chemistry, Dec-16, Volume: 47, Issue:26
Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database.
AID1188440Antimalarial activity against tightly synchronized Plasmodium falciparum HB3 assessed as parasite stage accumulation index at trophozoites stages at 10 uM treated at 18 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cy2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID587703Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human red blood cells assessed as inhibition of ring-stage parasite growth after 48 hrs by flow cytometry2011European journal of medicinal chemistry, Mar, Volume: 46, Issue:3
Design, synthesis and evaluation of 3-methylene-substituted indolinones as antimalarials.
AID1188459Antimalarial activity against tightly synchronized Plasmodium falciparum K1 assessed as parasite stage accumulation index at schizonts stages at 10 uM treated at 18 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cytolo2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID1188453Antimalarial activity against tightly synchronized Plasmodium falciparum K1 assessed as parasite stage accumulation index at early ring stages at 10 uM treated at 6 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cytolo2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID1887319Inhibition of SARS-COV2 main protease mediated cytotoxicity against human A549 cells transfected with pCMV3-2019-nCoV-3CLpro plasmid assessed as increase in cell number measured at 48 hrs in presence of buthionine sulfoximine by Nucblue dye based microsco
AID51350Inhibition of human cathepsin L.1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption.
AID50473Inhibitory activity against Cathepsin B at a concentration of 200 ng/mL1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
AID261350Inhibition of falcipain32006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory.
AID1458682Inhibition of recombinant Trypanosoma brucei rhodesiense rhodesain expressed in Pichia pastoris assessed as second order rate constant using Cbz-Phe-Arg-AMC as substrate after 30 mins by fluorescence assay2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs).
AID581964Antimicrobial activity against wild type Plasmodium falciparum HB3 infected in erythrocytes assessed as growth inhibition after 72 hrs by SYBR Green I-based fluorescence assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID597185Inhibition of Plasmodium falciparum falcipain 2 assessed as benzyloxycarbonyl-Phe-Leu-7-amino-4-methylcoumarin substrate hydrolysis after 30 mins by spectrofluorometry analysis2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Enone- and chalcone-chloroquinoline hybrid analogues: in silico guided design, synthesis, antiplasmodial activity, in vitro metabolism, and mechanistic studies.
AID694045Inhibition of recombinant Plasmodium falciparum falcipain 2 incubated with compound for 10 mins before addition of Z-Phe-Arg-AMC substrate by fluorescence spectrophotometry2012Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21
Pyrido[1,2-a]pyrimidin-4-ones as antiplasmodial falcipain-2 inhibitors.
AID1072082Inhibition of recombinant Plasmodium falciparum falcipain 2 after 30 mins by fluorescence assay2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Identification of diverse natural products as falcipain-2 inhibitors through structure-based virtual screening.
AID762418Inhibition of pig full length Cal1 after using SucLLVYAMC as substrate by FRET assay relative to E642013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
Design, synthesis, and optimization of novel epoxide incorporating peptidomimetics as selective calpain inhibitors.
AID762422Inhibition of human erythrocyte full length Cal1 using (DABCYL)TPLK-SPPSPR-(EDANS) as substrate after 20 min by FRET assay2013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
Design, synthesis, and optimization of novel epoxide incorporating peptidomimetics as selective calpain inhibitors.
AID279732Inhibition of recombinant CatA using [14C]GS-7340 substrate2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131.
AID1188454Antimalarial activity against tightly synchronized Plasmodium falciparum K1 assessed as parasite stage accumulation index at late ring stages at 10 uM treated at 6 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cytolog2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID1650052Inhibition of recombinant Plasmodium falciparum falcipain-3 expressed in bacterial expression system using ZFR-AMC as substrate at 100 uM measured for 30 mins by fluorimetric assay relative to control2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Identification of antimalarial leads with dual falcipain-2 and falcipain-3 inhibitory activity.
AID675030Inhibition of epimastigotes of Trypanosoma cruzi cruzipain using Bz-Pro-Phe-Arg-pNA as substrate at 10 uM by spectrophotometric analysis2012European journal of medicinal chemistry, Sep, Volume: 55Synthesis and biological evaluation of some novel 1-indanone thiazolylhydrazone derivatives as anti-Trypanosoma cruzi agents.
AID775981Cytotoxicity against mouse NIH/3T3 cells assessed as cell viability after 48 hrs by MTT assay2013European journal of medicinal chemistry, Nov, Volume: 69Squaric acid/4-aminoquinoline conjugates: novel potent antiplasmodial agents.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1673569Inhibition of recombinant Trypanosoma cruzi cruzain at 0.5 uM using Z-FR-AMC as substrate preincubated for 10 mins followed by substrate addition and measured at 12 sec interval for 5 mins by fluorimetric analysis relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.
AID282101Inhibition of Plasmodium falciparum recombinant falcipain-32004Journal of medicinal chemistry, Dec-16, Volume: 47, Issue:26
Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database.
AID587701Inhibition of Plasmodium falciparum falcipain 2 incubated with compound for 10 mins before addition of 25 uM Z-Leu-Arg-AMC substrate by fluorescence spectrophotometry2011European journal of medicinal chemistry, Mar, Volume: 46, Issue:3
Design, synthesis and evaluation of 3-methylene-substituted indolinones as antimalarials.
AID50477Inhibitory activity against Cathepsin B at a concentration of 50 ng/mL1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID473009Inhibition of Plasmodium falciparum recombinant falcipain-2 using Cbz-Leu-Arg-AMC as substrate by standard fluorescence assay2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID229263Ratio of IC50 for Cathepsin B to that for Cathepsin L1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption.
AID1188445Antimalarial activity against tightly synchronized Plasmodium falciparum W2 assessed as parasite stage accumulation index at late ring stages at 10 uM treated at 6 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cytolog2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID640998Inhibition of Plasmodium falciparum falcipain-2 using Z-Leu-Arg-AMC as substrate at 10 uM after 30 mins by spectrophotometric assay2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Design and synthesis of small molecular dual inhibitor of falcipain-2 and dihydrofolate reductase as antimalarial agent.
AID1188446Antimalarial activity against tightly synchronized Plasmodium falciparum W2 assessed as parasite stage accumulation index at trophozoites stages at 10 uM treated at 6 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cyto2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID315749Inhibition of Plasmodium falciparum recombinant falcipain-22008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Development of peptidomimetics with a vinyl sulfone warhead as irreversible falcipain-2 inhibitors.
AID1673571Inhibition of recombinant Trypanosoma brucei rhodesain expressed in Pichia pastoris at 0.5 uM using Z-FR-AMC as substrate preincubated for 10 mins followed by substrate addition and measured at 12 sec interval for 5 mins by fluorimetric analysis relative 2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.
AID351452Inhibition of Carica papaya papain by spectrofluorimetry2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Natural polyprenylated benzophenones inhibiting cysteine and serine proteases.
AID590137Inhibition of Plasmodium falciparum W2 recombinant falcipain-22011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Novel thiolactone-isatin hybrids as potential antimalarial and antitubercular agents.
AID421575Inhibition of Plasmodium falciparum recombinant falcipain-2 by microtiter plate spectrofluorimetry2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Identification of novel falcipain-2 inhibitors as potential antimalarial agents through structure-based virtual screening.
AID1458688Inhibition of recombinant Plasmodium falciparum falcipain-2 expressed in Escherichia coli M15(pREP4) using Cbz-Phe-Arg-AMC as substrate by fluorescence assay2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs).
AID1312178Inhibition of Trypanosoma cruzi cruzain at 100 uM using Z-Phe-Arg-aminomethylcoumarin as substrate measured after 5 mins in presence of 0.1% triton by spectrofluorimetry2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design, synthesis, molecular docking and biological evaluation of thiophen-2-iminothiazolidine derivatives for use against Trypanosoma cruzi.
AID667393Inhibition of heme polymerization at 1 mM after 48 hrs by spectrophotometry relative to chloroquine2012European journal of medicinal chemistry, Aug, Volume: 54Novel cinnamic acid/4-aminoquinoline conjugates bearing non-proteinogenic amino acids: towards the development of potential dual action antimalarials.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID762420Inhibition of pig full length Cal1 after using SucLLVYAMC as substrate by FRET assay2013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
Design, synthesis, and optimization of novel epoxide incorporating peptidomimetics as selective calpain inhibitors.
AID1188461Antimalarial activity against tightly synchronized Plasmodium falciparum K1 assessed as parasite stage accumulation index at schizonts stages at 10 uM treated at 30 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cytolo2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID1673570Inhibition of recombinant Trypanosoma brucei rhodesain expressed in Pichia pastoris at 0.5 uM using Z-FR-AMC as substrate and measured at 12 sec interval for 5 mins without preincubation by fluorimetric analysis relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.
AID1188492Antimalarial activity against Plasmodium falciparum W2 assessed as reduction in parasite stage accumulation index at 10 uM treated at 42 hrs post-invasion for 24 hrs by automated image mining based cytological profiling assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID775982Antiplasmodial activity against ring stage of chloroquine-resistant Plasmodium falciparum W2 infected in human RBC after 48 hrs by flow cytometric analysis2013European journal of medicinal chemistry, Nov, Volume: 69Squaric acid/4-aminoquinoline conjugates: novel potent antiplasmodial agents.
AID473014Antitrypanosomal activity against Trypanosoma brucei brucei2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID482876Inhibition of Plasmodium falciparum falcipain-2 after 12 hrs by fluorescence spectroscopy-based on-bead assay2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID775980Selectivity index, ratio of IC50 for HEK293T cells to IC50 for ring stage of Plasmodium falciparum W2 infected in human RBC2013European journal of medicinal chemistry, Nov, Volume: 69Squaric acid/4-aminoquinoline conjugates: novel potent antiplasmodial agents.
AID1754251Inhibition of recombinant Trypanosoma brucei rhodesain at 2 uM using Z-FR-AMC as substrate preincubated for 10 mins followed by substrate addition measured for 5 mins by fluorimetric analysis relative to control
AID46725Inhibition of Calpain-I receptor1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Synthesis and biological activity of a series of potent fluoromethyl ketone inhibitors of recombinant human calpain I.
AID454716Inhibition of Plasmodium falciparum falcipain-22009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Novel 2H-isoquinolin-3-ones as antiplasmodial falcipain-2 inhibitors.
AID1754249Inhibition of recombinant Trypanosoma brucei rhodesain using Z-FR-AMC as substrate preincubated for 10 mins followed by substrate addition measured for 5 mins by fluorimetric analysis relative to control
AID1650056Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes assessed as morphological abnormalities at 10 uM incubated for 54 hrs by giemsa staining based light microscopy2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Identification of antimalarial leads with dual falcipain-2 and falcipain-3 inhibitory activity.
AID279733Inhibition of crude human PBMC extract prodrug hydrolase using [14C]GS-7340 substrate2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131.
AID484235Inhibition of cathepsin B assessed as proteolytic activity at 40 nM by fluorimetric assay2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Design and synthesis of alpha-ketoamides as cathepsin S inhibitors with potential applications against tumor invasion and angiogenesis.
AID1650057Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes assessed as food-vacoules abnormalities at 10 uM incubated for 54 hrs by giemsa staining based light microscopy2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Identification of antimalarial leads with dual falcipain-2 and falcipain-3 inhibitory activity.
AID473010Inhibition of Plasmodium falciparum recombinant falcipain-3 by standard fluorescence assay2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID694043Inhibition of recombinant Plasmodium falciparum falcipain 2 at 2 uM preincubated for 10 mins before addition of Z-Phe-Arg-AMC substrate by fluorescence spectrophotometry2012Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21
Pyrido[1,2-a]pyrimidin-4-ones as antiplasmodial falcipain-2 inhibitors.
AID1188494Antimalarial activity against Plasmodium falciparum HB3 assessed as increase in schizonts parasite stage accumulation index at 10 uM treated at 42 hrs post-invasion for 24 hrs by automated image mining based cytological profiling assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID1312174Inhibition of Trypanosoma cruzi cruzain using Z-Phe-Arg-aminomethylcoumarin as substrate measured after 5 mins by spectrofluorimetry2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design, synthesis, molecular docking and biological evaluation of thiophen-2-iminothiazolidine derivatives for use against Trypanosoma cruzi.
AID1188455Antimalarial activity against tightly synchronized Plasmodium falciparum K1 assessed as parasite stage accumulation index at trophozoites stages at 10 uM treated at 6 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cyto2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID50478Inhibitory activity against Cathepsin B at a concentration of 70 ng/mL1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
AID1188441Antimalarial activity against tightly synchronized Plasmodium falciparum HB3 assessed as parasite stage accumulation index at schizonts stages at 10 uM treated at 18 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cytol2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID492329Inhibition of Plasmodium falciparum recombinant falcipain-2 after 10 min2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Constrained peptidomimetics as antiplasmodial falcipain-2 inhibitors.
AID1188490Antimalarial activity against Plasmodium falciparum K1 assessed as reduction in parasite stage accumulation index at 10 uM treated at 42 hrs post-invasion for 24 hrs by automated image mining based cytological profiling assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID279735Inhibition of porcine liver carboxylesterase using [14C]GS-7340 substrate2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131.
AID279769Inhibition of Toxoplasma gondii 2F1 invasion in HFF cells assessed as beta-galactosidase activity at 10 uM2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Cysteine protease inhibitors block Toxoplasma gondii microneme secretion and cell invasion.
AID635270Inhibition of Plasmodium falciparum falcipain-2 using Z-Leu-Arg-AMC as substrate after 10 mins by spectrofluorimetry2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Aza vinyl sulfones: synthesis and evaluation as antiplasmodial agents.
AID421574Inhibition of Plasmodium falciparum recombinant falcipain-2 at 10 uM by microtiter plate spectrofluorimetry2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Identification of novel falcipain-2 inhibitors as potential antimalarial agents through structure-based virtual screening.
AID248410Inhibitory concentration against Plasmodium falciparum in FACS2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives.
AID50472Inhibitory activity against Cathepsin B at a concentration of 1 ng/mL1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
AID1673568Inhibition of recombinant Trypanosoma cruzi cruzain at 0.5 uM using Z-FR-AMC as substrate and measured at 12 sec interval for 5 mins without preincubation by fluorimetric analysis relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.
AID1188457Antimalarial activity against tightly synchronized Plasmodium falciparum K1 assessed as parasite stage accumulation index at late ring stages at 10 uM treated at 18 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cytolo2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID1673587Inhibition of recombinant Trypanosoma cruzi cruzain at 0.5 uM preincubated for 10 mins in absence of Triton X-100 relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.
AID1188443Antimalarial activity against tightly synchronized Plasmodium falciparum HB3 assessed as parasite stage accumulation index at schizonts stages at 10 uM treated at 30 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cytol2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID1887315Inhibition of SARS-COV2 main protease mediated cytotoxicity against human HepG2 cells transfected with pCMV3-2019-nCoV-3CLpro plasmid assessed as increase in cell number at 5 uM measured at 48 hrs by Nucblue dye based microscopic analysis
AID50463Inhibitory activity against Cathepsin B was determined1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
AID1650051Inhibition of recombinant Plasmodium falciparum falcipain-2 expressed in bacterial expression system using ZFR-AMC as substrate at 100 uM measured for 30 mins by fluorimetric assay relative to control2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Identification of antimalarial leads with dual falcipain-2 and falcipain-3 inhibitory activity.
AID50479Inhibitory activity against Cathepsin B at a concentration of 7 ng/mL1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
AID1754247Inhibition of recombinant Trypanosoma cruzi cruzain using Z-FR-AMC as substrate preincubated for 10 mins followed by substrate addition measured for 5 mins by fluorimetric analysis relative to control
AID1312171Inhibition of Trypanosoma cruzi cruzain at 100 uM pre-incubated for 10 mins followed by addition of Z-Phe-Arg-aminomethylcoumarin as substrate measured after 5 mins by spectrofluorimetry2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design, synthesis, molecular docking and biological evaluation of thiophen-2-iminothiazolidine derivatives for use against Trypanosoma cruzi.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID351460Inhibition of Carica papaya papain at 0.2 uM preincubated for 5 mins before addition of increasing concentration of substrate Z-FR-AMC2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Natural polyprenylated benzophenones inhibiting cysteine and serine proteases.
AID360106Inhibition of human recombinant cathepsin H after 10 mins2007The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29
Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.
AID1188495Antimalarial activity against Plasmodium falciparum W2 assessed as increase in schizonts parasite stage accumulation index at 10 uM treated at 42 hrs post-invasion for 24 hrs by automated image mining based cytological profiling assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID775983Inhibition of Plasmodium falciparum falcipain-2 using Z-Leu-Arg-AMC as substrate preincubated for 10 mins followed by substrate addition by spectrofluorometric analysis2013European journal of medicinal chemistry, Nov, Volume: 69Squaric acid/4-aminoquinoline conjugates: novel potent antiplasmodial agents.
AID1673608Inhibition of rat cathepsin B at 1 uM using Z-FR-AMC as substrate measured after 15 mins without preincubation by microplate reader based assay relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.
AID50471Inhibitory activity against Cathepsin B at a concentration of 10 ng/mL1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
AID1188458Antimalarial activity against tightly synchronized Plasmodium falciparum K1 assessed as parasite stage accumulation index at trophozoites stages at 10 uM treated at 18 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cyt2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID1663653Inhibition of Trypanosoma brucei rhodesain at 10 uM measured after 1 hr relative to control2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
Vinyl sulfone-based inhibitors of trypanosomal cysteine protease rhodesain with improved antitrypanosomal activities.
AID454717Antiplasmodial activity against Plasmodium falciparum FcBR2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Novel 2H-isoquinolin-3-ones as antiplasmodial falcipain-2 inhibitors.
AID1188452Antimalarial activity against tightly synchronized Plasmodium falciparum W2 assessed as parasite stage accumulation index at schizonts stages at 10 uM treated at 30 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cytolo2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID1673603Inhibition of recombinant human cathepsin S expressed in Escherichia coli at 1 uM using Z-VVR-AMC as substrate preincubated for 10 mins followed by substrate addition and measured after 15 mins by microplate reader based assay relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID492330Ratio of Kinact to Ki for Plasmodium falciparum recombinant falcipain-2 after 10 min2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Constrained peptidomimetics as antiplasmodial falcipain-2 inhibitors.
AID1673586Inhibition of recombinant Trypanosoma cruzi Cruzain at 0.5 uM preincubated for 10 mins in presence of 0.01% Triton X-100 relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.
AID360103Inhibition of human recombinant cathepsin B after 10 mins2007The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29
Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.
AID1458684Inhibition of human cathepsin L assessed as first order rate constant using Cbz-Phe-Arg-AMC as substrate after 10 mins by fluorescence assay2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs).
AID484234Inhibition of cathepsin L assessed as proteolytic activity at 40 nM by fluorimetric assay2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Design and synthesis of alpha-ketoamides as cathepsin S inhibitors with potential applications against tumor invasion and angiogenesis.
AID1170651Inhibition of cathepsin B (unknown origin) using fluorometric Z-Phe-Arg-AMC as substrate by spectrofluorimetry2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Structures and bioactivities of dihydrochalcones from Metrodorea stipularis.
AID1854036Inhibition of cathepsin L (unknown origin) using Cbz-Phe-Arg-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by fluorometric assay
AID1673585Inhibition of recombinant Trypanosoma cruzi cruzain at 0.5 uM preincubated for 10 mins in presence of 0.1% Triton X-100 relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.
AID1188491Antimalarial activity against Plasmodium falciparum HB3 assessed as reduction in parasite stage accumulation index at 10 uM treated at 42 hrs post-invasion for 24 hrs by automated image mining based cytological profiling assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID1188437Antimalarial activity against tightly synchronized Plasmodium falciparum HB3 assessed as parasite stage accumulation index at trophozoites stages at 10 uM treated at 6 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cyt2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID490971Antiplasmodial activity against Plasmodium falciparum FCBR infected in human RBC2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis of novel peptidomimetics as inhibitors of protozoan cysteine proteases falcipain-2 and rhodesain.
AID1188450Antimalarial activity against tightly synchronized Plasmodium falciparum W2 assessed as parasite stage accumulation index at schizonts stages at 10 uM treated at 18 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cytolo2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID1544403Anti-angiogenic activity in human HUVEC cells assessed as inhibition in pro-angiogenic structures formation in presence of fetal calf serum at 5 uM incubated for 18 hrs by inverted light microscopy based matrigel assay2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Antitumor effect of chiral organotelluranes elicited in a murine melanoma model.
AID1754260Reversible inhibition of recombinant Trypanosoma brucei rhodesain using Z-FR-AMC as substrate measured for 30 mins by fluorimetric analysis
AID490970Inhibition of Plasmodium falciparum falcipain-2 after 10 to 15 min2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis of novel peptidomimetics as inhibitors of protozoan cysteine proteases falcipain-2 and rhodesain.
AID1188460Antimalarial activity against tightly synchronized Plasmodium falciparum K1 assessed as parasite stage accumulation index at trophozoites stages at 10 uM treated at 30 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cyt2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID473011Inhibition of Trypanosoma brucei rhodesiense recombinant rhodesain by standard fluorescence assay2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID240752Inhibitory concentration against recombinant Falcipain-22005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives.
AID1170652Inhibition of cathepsin L (unknown origin) using fluorometric Z-Phe-Arg-AMC as substrate by spectrofluorimetry2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Structures and bioactivities of dihydrochalcones from Metrodorea stipularis.
AID386436Inhibition of DPAP1 assessed as blocking of release of beta-naphthylamine from Ala-Pro-Ala-betaNA substrate at 1 uM in presence of recombinant Plasmodium falciparum aminopeptidase P2007The Journal of biological chemistry, Dec-07, Volume: 282, Issue:49
Roles for two aminopeptidases in vacuolar hemoglobin catabolism in Plasmodium falciparum.
AID414571Inhibition of Plasmodium falciparum falcipain-22009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Novel peptidomimetics containing a vinyl ester moiety as highly potent and selective falcipain-2 inhibitors.
AID1854039Inhibition of cathepsin B (unknown origin) using Cbz-Phe-Arg-AMC as substrate at 6.25 nM preincubated for 5 mins followed by substrate addition and measured after 10 mins by fluorometric assay
AID1188436Antimalarial activity against tightly synchronized Plasmodium falciparum HB3 assessed as parasite stage accumulation index at late ring stages at 10 uM treated at 6 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cytolo2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID1673609Inhibition of rat cathepsin B at 1 uM using Z-FR-AMC as substrate preincubated for 10 mins followed by substrate addition and measured after 15 mins by microplate reader based assay relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.
AID1458683Inhibition of human cathepsin L using Cbz-Phe-Arg-AMC as substrate after 10 mins by fluorescence assay2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs).
AID461170Antimicrobial activity against chloroquine-resistant Plasmodium falciparum W22010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Synthesis, antimalarial and antitubercular activity of acetylenic chalcones.
AID482882Antiplasmodial activity against Plasmodium falciparum FCBR by fluorometric method2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID762419Inhibition of papain after using SucLLVYAMC as substrate by FRET assay2013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
Design, synthesis, and optimization of novel epoxide incorporating peptidomimetics as selective calpain inhibitors.
AID1754250Inhibition of recombinant Trypanosoma cruzi cruzain at 2 uM using Z-FR-AMC as substrate preincubated for 10 mins followed by substrate addition measured for 5 mins by fluorimetric analysis relative to control
AID386435Inhibition of DPAP1 assessed as blocking of release of beta-naphthylamine from Ala-Pro-Ala-betaNA substrate at 1 uM2007The Journal of biological chemistry, Dec-07, Volume: 282, Issue:49
Roles for two aminopeptidases in vacuolar hemoglobin catabolism in Plasmodium falciparum.
AID635272Inhibition of papaya papain using Z-Leu-Leu-Arg-AMC as substrate after 30 mins by spectrofluorometry2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Aza vinyl sulfones: synthesis and evaluation as antiplasmodial agents.
AID344824Inhibition of SARS coronavirus 3C-like protease R188I mutant at 5.6 mM by HPLC2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant.
AID1188448Antimalarial activity against tightly synchronized Plasmodium falciparum W2 assessed as parasite stage accumulation index at late ring stages at 10 uM treated at 18 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cytolo2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID1458695Inhibition of recombinant Trypanosoma brucei rhodesiense rhodesain expressed in Pichia pastoris using Cbz-Phe-Arg-AMC as substrate after 30 min by fluorescence assay2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs).
AID1673595Inhibition of recombinant Trypanosoma cruzi cruzain at 0.5 uM preincubated with enzyme for 5 mins followed by substrate addition in absence of BSA relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.
AID261349Inhibition of falcipain22006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID635271Antiplasmodial activity against ring stage Plasmodium falciparum W2 infected in human red blood cells after 48 hrs by flow cytometry2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Aza vinyl sulfones: synthesis and evaluation as antiplasmodial agents.
AID50272Inhibition of human cathepsin B1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption.
AID1243757Cytotoxicity against mouse peritoneal macrophages assessed as reduction in cell viability incubated for 72 hrs by MTT assay2015European journal of medicinal chemistry, Aug-28, Volume: 101Leishmanicidal, antiproteolytic, and mutagenic evaluation of alkyltriazoles and alkylphosphocholines.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1312168Inhibition of Trypanosoma cruzi cruzain at 100 uM using Z-Phe-Arg-aminomethylcoumarin as substrate measured after 5 mins by spectrofluorimetry2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design, synthesis, molecular docking and biological evaluation of thiophen-2-iminothiazolidine derivatives for use against Trypanosoma cruzi.
AID360105Inhibition of human recombinant cathepsin L after 10 mins2007The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29
Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.
AID1243758Selectivity index, ratio of CC50 for mouse peritoneal macrophages to IC50 for Leishmania amazonensis MHOM/BR/71973/M2269 amastigotes infected in mouse peritoneal macrophages2015European journal of medicinal chemistry, Aug-28, Volume: 101Leishmanicidal, antiproteolytic, and mutagenic evaluation of alkyltriazoles and alkylphosphocholines.
AID667396Inhibition of Plasmodium falciparum falcipain 3 using substrate benzoxycarbonyl-Leu-Arg-7-amino-4-methyl-coumarin preincubated for 30 mins before substrate addition by fluorescence assay2012European journal of medicinal chemistry, Aug, Volume: 54Novel cinnamic acid/4-aminoquinoline conjugates bearing non-proteinogenic amino acids: towards the development of potential dual action antimalarials.
AID581962Antimicrobial activity against leupeptin resistant-Plasmodium falciparum HB3-leuR1 mutant infected in erythrocytes assessed as growth inhibition after 72 hrs by SYBR Green I-based fluorescence assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID1188449Antimalarial activity against tightly synchronized Plasmodium falciparum W2 assessed as parasite stage accumulation index at trophozoites stages at 10 uM treated at 18 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cyt2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID600084Inhibition of Plasmodium falciparum recombinant falcipain-2 incubated for 30 mins at room temperature before addition of substrate benzoxycarbonyl-Leu-Arg-7-amino-4-methyl-coumarin by spectrofluorometry2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Artemisinin-dipeptidyl vinyl sulfone hybrid molecules: design, synthesis and preliminary SAR for antiplasmodial activity and falcipain-2 inhibition.
AID173842Percentage of control was measured on rat liver cathepsin B by a single intraperitoneal dose of 10 mg/kg1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
In vivo inhibition of cathepsin B by peptidyl (acyloxy)methyl ketones.
AID473013Antiplasmodial activity against Plasmodium falciparum FCBR by flow cytometry2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID1458685Inhibition of human cathepsin L assessed as second order rate constant using Cbz-Phe-Arg-AMC as substrate after 10 mins by fluorescence assay2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs).
AID1312176Inhibition of Trypanosoma cruzi cruzain at 100 uM using Z-Phe-Arg-aminomethylcoumarin as substrate measured after 5 mins in presence of 0.01% triton by spectrofluorimetry2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design, synthesis, molecular docking and biological evaluation of thiophen-2-iminothiazolidine derivatives for use against Trypanosoma cruzi.
AID360104Inhibition of human recombinant cathepsin S after 10 mins2007The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29
Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.
AID1188438Antimalarial activity against tightly synchronized Plasmodium falciparum HB3 assessed as parasite stage accumulation index at schizonts stages at 10 uM treated at 6 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cytolo2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID667395Inhibition of Plasmodium falciparum falcipain 2 using substrate benzoxycarbonyl-Leu-Arg-7-amino-4-methyl-coumarin preincubated for 30 mins before substrate addition by fluorescence assay2012European journal of medicinal chemistry, Aug, Volume: 54Novel cinnamic acid/4-aminoquinoline conjugates bearing non-proteinogenic amino acids: towards the development of potential dual action antimalarials.
AID600086Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 synchronized ring stage parasites infected in erythrocytes assessed as reduction in parasitemia after 48 hrs by Giemsa staining2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Artemisinin-dipeptidyl vinyl sulfone hybrid molecules: design, synthesis and preliminary SAR for antiplasmodial activity and falcipain-2 inhibition.
AID421576Inhibition of Plasmodium falciparum recombinant falcipain-2 at 10 uM after dialysis in refolding buffer for 8 hrs by SDS-PAGE2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Identification of novel falcipain-2 inhibitors as potential antimalarial agents through structure-based virtual screening.
AID303390Inhibition of Trypanosoma cruzi Tulahuen 2 cruzipain at 10 uM2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
In vivo anti-Chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives.
AID1673602Inhibition of recombinant human cathepsin S expressed in Escherichia coli at 1 uM using Z-VVR-AMC as substrate and measured after 15 mins without preincubation by microplate reader based assay relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.
AID1188493Antimalarial activity against Plasmodium falciparum K1 assessed as increase in schizonts parasite stage accumulation index at 10 uM treated at 42 hrs post-invasion for 24 hrs by automated image mining based cytological profiling assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID50476Inhibitory activity against Cathepsin B at a concentration of 4 ng/mL1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
AID278816Antimalarial activity against Plasmodium falciparum D102007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.
AID461168Inhibition of Plasmodium falciparum falcipain-22010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Synthesis, antimalarial and antitubercular activity of acetylenic chalcones.
AID1188456Antimalarial activity against tightly synchronized Plasmodium falciparum K1 assessed as parasite stage accumulation index at schizonts stages at 10 uM treated at 6 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cytolog2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID279731Inhibition of purified prodrug hydrolase using [14C]GS-7340 substrate2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131.
AID351462Inhibition of Carica papaya papain at 0.5 uM preincubated before DTT addition by fluorescence measurement2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Natural polyprenylated benzophenones inhibiting cysteine and serine proteases.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1188435Antimalarial activity against tightly synchronized Plasmodium falciparum HB3 assessed as parasite stage accumulation index at early ring stages at 10 uM treated at 6 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cytol2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID1188439Antimalarial activity against tightly synchronized Plasmodium falciparum HB3 assessed as parasite stage accumulation index at late ring stages at 10 uM treated at 18 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cytol2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID1673594Inhibition of recombinant Trypanosoma cruzi cruzain at 0.5 uM preincubated with BSA for 5 mins followed by incubation with enzyme for 5 mins followed by substrate addition relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.
AID1188444Antimalarial activity against tightly synchronized Plasmodium falciparum W2 assessed as parasite stage accumulation index at early ring stages at 10 uM treated at 6 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cytolo2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID315750Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs in Malstat assay2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Development of peptidomimetics with a vinyl sulfone warhead as irreversible falcipain-2 inhibitors.
AID1754259Inhibition of recombinant Trypanosoma brucei rhodesain at 0.1 uM using Z-FR-AMC as substrate preincubated for 10 mins followed by substrate addition by fluorimetric analysis relative to control
AID667394Antiplasmodial activity against chloroquine-resistant blood-stage Plasmodium falciparum W2 after 48 hrs by flow cytometric analysis2012European journal of medicinal chemistry, Aug, Volume: 54Novel cinnamic acid/4-aminoquinoline conjugates bearing non-proteinogenic amino acids: towards the development of potential dual action antimalarials.
AID1887316Inhibition of SARS-COV2 main protease mediated cytotoxicity against human A549 cells transfected with pCMV3-2019-nCoV-3CLpro plasmid assessed as increase in cell number at 5 uM measured at 48 hrs by Nucblue dye based microscopic analysis
AID50474Inhibitory activity against Cathepsin B at a concentration of 400 ng/mL1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
AID1243759Inhibition of Leishmania mexicana cysteine protease r-CPB2.8 using Z-FR-AMC fluorogenic substrate by spectrofluorometry2015European journal of medicinal chemistry, Aug-28, Volume: 101Leishmanicidal, antiproteolytic, and mutagenic evaluation of alkyltriazoles and alkylphosphocholines.
AID775984Inhibition of papaya papain using Z-Leu-Leu-Arg-AMC as substrate after 30 mins by fluorescence microplate reader analysis2013European journal of medicinal chemistry, Nov, Volume: 69Squaric acid/4-aminoquinoline conjugates: novel potent antiplasmodial agents.
AID1854040Inhibition of cathepsin L (unknown origin) using Cbz-Phe-Arg-AMC as substrate at 6.25 nM preincubated for 5 mins followed by substrate addition and measured after 10 mins by fluorometric assay
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID360102Inhibition of human recombinant cathepsin C after 10 mins2007The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29
Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.
AID482877Inhibition of Plasmodium falciparum recombinant falcipain-2 expressed in Escherichia coli at 100 uM after 20 min by spectrofluorometry2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID278818Antimalarial activity against Plasmodium falciparum Dd22007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.
AID1188451Antimalarial activity against tightly synchronized Plasmodium falciparum W2 assessed as parasite stage accumulation index at trophozoites stages at 10 uM treated at 30 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cyt2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID454719Inhibition of human cathepsin B2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Novel 2H-isoquinolin-3-ones as antiplasmodial falcipain-2 inhibitors.
AID24387The inhibition against liver metastases at 100 ug/mL.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID640999Inhibition of Plasmodium falciparum falcipain-2 using Z-Leu-Arg-AMC as substrate after 30 mins by spectrophotometric assay2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Design and synthesis of small molecular dual inhibitor of falcipain-2 and dihydrofolate reductase as antimalarial agent.
AID603219Inhibition of Plasmodium falciparum recombinant refolded falcipain 2 activity using ZFR-AMC as a substrate after 30 mins by fluorimetric assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Design and synthesis of protein-protein interaction mimics as Plasmodium falciparum cysteine protease, falcipain-2 inhibitors.
AID278817Antimalarial activity against Plasmodium falciparum FAC82007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.
AID454720Inhibition of human cathepsin L2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Novel 2H-isoquinolin-3-ones as antiplasmodial falcipain-2 inhibitors.
AID1493103Inhibition of cathepsin D in human MDA-MB-231 cells assessed as reduction in cysteine cathepsin activity up to 10 uM using Z-Phe-Arg-AMC as substrate pretreated for 3 days under pH 6.6 conditioned media followed by substrate addition measured at 5 mins in2017Journal of natural products, 11-22, Volume: 80, Issue:11
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.
AID1854035Inhibition of cathepsin B (unknown origin) using Cbz-Phe-Arg-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by fluorometric assay
AID587702Inhibition of Plasmodium falciparum falcipain 3 incubated with compound for 10 mins before addition of 25 uM Z-Leu-Arg-AMC substrate by fluorescence spectrophotometry2011European journal of medicinal chemistry, Mar, Volume: 46, Issue:3
Design, synthesis and evaluation of 3-methylene-substituted indolinones as antimalarials.
AID600085Inhibition of Plasmodium chabaudi recombinant chabaupain expressed in Escherichia coli2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Artemisinin-dipeptidyl vinyl sulfone hybrid molecules: design, synthesis and preliminary SAR for antiplasmodial activity and falcipain-2 inhibition.
AID775979Cytotoxicity against HEK293T cells assessed as cell viability after 48 hrs by MTT assay2013European journal of medicinal chemistry, Nov, Volume: 69Squaric acid/4-aminoquinoline conjugates: novel potent antiplasmodial agents.
AID407719Inhibition of Plasmodium falciparum falcipain-2 in RBC assessed as hemoglobin degradation after 24 hrs by SDS-PAGE2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
A prodomain peptide of Plasmodium falciparum cysteine protease (falcipain-2) inhibits malaria parasite development.
AID762421Binding affinity to recombinant rat full length Cal1 catalytic domain expressed in Escherichia coli BL21(DE3) assessed as modification of active site cysteine at 1 uM by LC-MS/MS analysis2013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
Design, synthesis, and optimization of novel epoxide incorporating peptidomimetics as selective calpain inhibitors.
AID421577Binding affinity to Plasmodium falciparum recombinant falcipain-2 by isothermal titration calorimetry2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Identification of novel falcipain-2 inhibitors as potential antimalarial agents through structure-based virtual screening.
AID1243756Leishmanicidal activity against Leishmania amazonensis MHOM/BR/71973/M2269 amastigotes infected in mouse peritoneal macrophages assessed as reduction in surviving parasites incubated for 72 hrs by Giemsa staining based optical light microscopy2015European journal of medicinal chemistry, Aug-28, Volume: 101Leishmanicidal, antiproteolytic, and mutagenic evaluation of alkyltriazoles and alkylphosphocholines.
AID279734Inhibition of human leukocyte elastase using [14C]GS7340 substrate2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131.
AID1188447Antimalarial activity against tightly synchronized Plasmodium falciparum W2 assessed as parasite stage accumulation index at schizonts stages at 10 uM treated at 6 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cytolog2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID1458681Inhibition of recombinant Trypanosoma brucei rhodesiense rhodesain expressed in Pichia pastoris assessed as first order rate constant using Cbz-Phe-Arg-AMC as substrate after 30 mins by fluorescence assay2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs).
AID482880Inhibition of Plasmodium falciparum falcipain-2 by cell-based assay2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID1188442Antimalarial activity against tightly synchronized Plasmodium falciparum HB3 assessed as parasite stage accumulation index at trophozoites stages at 10 uM treated at 30 hrs post-invasion for continuous duration of 36 hrs by automated image mining based cy2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
AID1754258Inhibition of recombinant Trypanosoma brucei rhodesain at 0.1 uM using Z-FR-AMC as substrate by fluorimetric analysis relative to control
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (461)

TimeframeStudies, This Drug (%)All Drugs %
pre-199050 (10.85)18.7374
1990's152 (32.97)18.2507
2000's133 (28.85)29.6817
2010's114 (24.73)24.3611
2020's12 (2.60)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.95 (24.57)
Research Supply Index6.17 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index64.68 (26.88)
Search Engine Supply Index2.06 (0.95)

This Compound (40.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.21%)5.53%
Reviews4 (0.84%)6.00%
Case Studies1 (0.21%)4.05%
Observational0 (0.00%)0.25%
Other471 (98.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]